February 3, 2022

MHRA approval of the Novavax COVID-19 vaccine, Nuvaxovid

The MHRA has just approved the Novavax COVID-19 vaccine, Nuvaxovid, for use in people aged 18 and over for a first and second dose. Novavax have put forward some experts who can answer journalists questions about the vaccine, and the MHRA approval.

Speakers included:

Prof Paul Heath, Principal Investigator of the UK arm of the Novavax vaccine trial, and Professor of Paediatric Infectious Diseases and Director of the Vaccine Institute, St George’s, University of London

Filip Dubovsky, Chief Medical Officer, Novavax

Silvia Taylor, Head of Corporate Affairs, Novavax

This Briefing was accompanied by an SMC Roundup of Comments.